Identification

Name
Amoxapine
Accession Number
DB00543  (APRD00142)
Type
Small Molecule
Groups
Approved
Description

Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.

Structure
Thumb
Synonyms
  • 2-Chloro-11-(1-piperazinyl)dibenz(b,F)(1,4)oxazepine
  • Amoxapin
  • Amoxapina
  • Amoxapinum
  • Amoxepine
  • Desmethylloxapin
External IDs
CL 67,772 / CL 67772 / CL-67,772 / CL-67772
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Asendin - Tab 100mgTablet100 mgOralWyeth Ayerst Canada Inc.1999-04-122002-06-10Canada
Asendin - Tab 25mgTablet25 mgOralWyeth Ayerst Canada Inc.1997-02-042000-08-02Canada
Asendin - Tab 50mgTablet50 mgOralWyeth Ayerst Canada Inc.1997-04-292001-12-12Canada
Asendin Tab 100mgTablet100 mgOralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Asendin Tab 25mgTablet25 mgOralLederle Cyanamid Canada Inc.1981-12-311997-08-14Canada
Asendin Tab 50mgTablet50 mgOralLederle Cyanamid Canada Inc.1981-12-311999-04-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmoxapineTablet50 mg/1OralPhysicians Total Care, Inc.2011-05-12Not applicableUs
AmoxapineTablet50 mg/1OralActavis Pharma Company1992-08-28Not applicableUs
AmoxapineTablet150 mg/1OralActavis Pharma Company1992-08-28Not applicableUs
AmoxapineTablet25 mg/1OralActavis Pharma Company1992-08-28Not applicableUs
AmoxapineTablet100 mg/1OralActavis Pharma Company1992-08-28Not applicableUs
International/Other Brands
Adisen (Kun Wha) / Amolife / Amoxan (Wyeth KK) / Asendin / Asendis / Défanyl (Eisai) / Demolox (Wyeth) / Oxamine (Psyco Remedies) / Oxcap
Categories
UNII
R63VQ857OT
CAS number
14028-44-5
Weight
Average: 313.781
Monoisotopic: 313.098189856
Chemical Formula
C17H16ClN3O
InChI Key
QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
IUPAC Name
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene
SMILES
ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1

Pharmacology

Indication

For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.

Associated Conditions
Pharmacodynamics

Amoxapine is a tricyclic antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzodiazepines, dibenzocycloheptenes, and dibenzoxepines. It has a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of nor-epinephirine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine

Mechanism of action

Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

TargetActionsOrganism
USodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
UD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UGamma-aminobutyric acid receptor subunit alpha-1
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-1 adrenergic receptors
antagonist
Human
UMuscarinic acetylcholine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2B
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
UAlpha-2 adrenergic receptors
antagonist
Human
UHistamine H4 receptor
binder
Human
UGABA-A receptor (anion channel)
binder
Human
USodium-dependent dopamine transporter
binder
Human
Absorption

Rapidly and almost completely absorbed from the GI tract. Peak plasma concentrations occur within 1-2 hours of oral administration of a single dose.

Volume of distribution

Widely distributed in body tissues with highest concentrations found in lungs, spleen, kidneys, heart, and brain. Lower concentrations can be detected in testes and muscle.

Protein binding

In vitro tests show that amoxapine binding to human plasma proteins is approximately 90%.

Metabolism

Amoxapine is almost completely metabolized in the liver to its major metabolite, 8-hydroxyamoxapine, and a minor metabolite, 7-hydroxyamoxapine. Both metabolites are phamacologically inactive and have half-lives of approximately 30 and 6.5 hours, respectively.

Route of elimination

60-69% of a single orally administered dose of amoxapine is excreted in urine, principally as conjugated metabolites. 7-18% of the dose is excrete feces mainly as unconjugated metabolites. Less than 5% of the dose is excreted as unchanged drug in urine.

Half life

8 hours

Clearance
Not Available
Toxicity

Toxic manifestations of amoxapine overdosage differ significantly from those of other tricyclic antidepressants. Serious cardiovascular effects are seldom if ever observed. However, CNS effects, particularly grand mal convulsions, occur frequently, and treatment should be directed primarily toward prevention or control of seizures. Status epilepticus may develop and constitutes a neurologic emergency. Coma and acidosis are other serious complications of substantial amoxapine overdosage in some cases. Renal failure may develop two to five days after toxic overdose in patients who may appear otherwise recovered. Acute tubular necrosis with rhabdomuolysis and myolobinurla is the most common renal complication in such cases. This reaction probably occurs in less than 5% of overdose cases, and typically in those who have experienced multiple seizures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Amoxapine can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Amoxapine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineAmoxapine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAmoxapine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Amoxapine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineAmoxapine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Amoxapine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineAmoxapine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAmoxapine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Amoxapine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Amoxapine.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Abediterol.Investigational
AbirateroneThe serum concentration of Amoxapine can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
AcenocoumarolAmoxapine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineAmoxapine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amoxapine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Acetophenazine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Amoxapine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Adipiplon.Investigational
AdrafinilAmoxapine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAmoxapine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Agomelatine.Approved, Investigational
AlaproclateAlaproclate may increase the serotonergic activities of Amoxapine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amoxapine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Amoxapine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Amoxapine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Amoxapine can be increased when it is combined with Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Amoxapine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Amoxapine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amoxapine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amoxapine.Approved
AmibegronAmoxapine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe metabolism of Amoxapine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Amisulpride.Approved, Investigational
AmitrazAmoxapine may decrease the antihypertensive activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Amoxapine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Amoxapine can be increased when combined with Amobarbital.Approved, Illicit
AmperozideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the serotonergic activities of Amoxapine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amoxapine can be increased when it is combined with Amprenavir.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Amoxapine is combined with Amrinone.Approved
AnagrelideAmoxapine may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineAmoxapine may decrease the vasoconstricting activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Amoxapine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Amoxapine can be increased when it is combined with Apixaban.Approved
ApomorphineAmoxapine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineAmoxapine may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Amoxapine can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
AranidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Aranidipine.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Arbutamine.Approved
ArformoterolThe therapeutic efficacy of Arformoterol can be decreased when used in combination with Amoxapine.Approved, Investigational
ArgatrobanThe serum concentration of Amoxapine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Amoxapine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Amoxapine.Investigational
Arsenic trioxideAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAmoxapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Articaine.Approved
AsenapineAsenapine may increase the antihypertensive activities of Amoxapine.Approved
AsunaprevirThe serum concentration of Amoxapine can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Amoxapine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
AtomoxetineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Amoxapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Azaperone.Investigational, Vet Approved
AzelastineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Amoxapine is combined with Azimilide.Investigational
AzithromycinAmoxapine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Amoxapine.Approved
BambuterolThe therapeutic efficacy of Bambuterol can be decreased when used in combination with Amoxapine.Approved, Investigational
BarbexacloneThe metabolism of Amoxapine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Amoxapine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Barnidipine.Approved
BatimastatThe serum concentration of Amoxapine can be increased when it is combined with Batimastat.Experimental
Beclomethasone dipropionateThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Amoxapine.Approved, Investigational
BedaquilineAmoxapine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
BenazeprilThe serum concentration of Amoxapine can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Amoxapine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Amoxapine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Amoxapine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Benzocaine.Approved, Investigational
BenzphetamineAmoxapine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Amoxapine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineAmoxapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Amoxapine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Amoxapine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
BethanidineAmoxapine may decrease the antihypertensive activities of Bethanidine.Approved
BevantololBevantolol may increase the antihypertensive activities of Amoxapine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bifeprunox.Investigational
BioallethrinThe risk or severity of hypotension can be increased when Amoxapine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
BitolterolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Amoxapine can be increased when it is combined with Bivalirudin.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Amoxapine.Investigational
BoceprevirThe serum concentration of Amoxapine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
BrexpiprazoleAmoxapine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Amoxapine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amoxapine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromisoval.Experimental
BromocriptineAmoxapine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Amoxapine.Investigational
BudesonideThe therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine.Approved
BufuralolBufuralol may increase the orthostatic hypotensive activities of Amoxapine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Amoxapine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
BuprenorphineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Amoxapine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Amoxapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Amoxapine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amoxapine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amoxapine.Approved
CamostatThe serum concentration of Amoxapine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Amoxapine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Amoxapine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Amoxapine is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Amoxapine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Amoxapine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Amoxapine is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.Approved
CaroverineThe risk or severity of hypotension can be increased when Amoxapine is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the serotonergic activities of Amoxapine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Amoxapine.Approved, Investigational
CelecoxibThe metabolism of Amoxapine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
CeritinibAmoxapine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amoxapine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amoxapine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Amoxapine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chlorphenamine.Approved
ChlorphentermineAmoxapine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Amoxapine.Experimental
ChlorpromazineAmoxapine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine.Approved
CholecalciferolThe metabolism of Amoxapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Amoxapine can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe therapeutic efficacy of Ciclesonide can be decreased when used in combination with Amoxapine.Approved, Investigational
CilastatinThe serum concentration of Amoxapine can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Amoxapine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Amoxapine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Amoxapine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinAmoxapine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineAmoxapine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideAmoxapine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram.Approved
ClarithromycinAmoxapine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Amoxapine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clidinium.Approved
ClobazamThe metabolism of Amoxapine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Amoxapine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clonazepam.Approved, Illicit
ClonidineAmoxapine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.Approved, Illicit
ClorindioneAmoxapine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Amoxapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the antihypertensive activities of Amoxapine.Approved
CobicistatThe serum concentration of Amoxapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Amoxapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amoxapine.Approved, Illicit
CrizotinibAmoxapine may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe metabolism of Amoxapine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyamemazine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Amoxapine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Amoxapine.Approved
Dabigatran etexilateThe serum concentration of Amoxapine can be increased when it is combined with Dabigatran etexilate.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Amoxapine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.Investigational
DarexabanThe serum concentration of Amoxapine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Amoxapine can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Amoxapine can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Amoxapine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Amoxapine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Amoxapine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Amoxapine.Approved, Investigational
DetomidineAmoxapine may decrease the antihypertensive activities of Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.Approved
DexmedetomidineAmoxapine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amoxapine.Approved, Investigational
DextroamphetamineAmoxapine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amoxapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amoxapine.Approved, Illicit, Investigational, Vet Approved
DicoumarolAmoxapine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Amoxapine is combined with Diethyl ether.Experimental
DiethylpropionAmoxapine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amoxapine.Approved, Illicit
DihydroergotamineAmoxapine may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Amoxapine is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dimenhydrinate.Approved
DiphenadioneAmoxapine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Amoxapine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amoxapine.Approved, Illicit
DipivefrinAmoxapine may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Amoxapine.Approved
DisopyramideAmoxapine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dixyrazine.Experimental
DL-MethylephedrineAmoxapine may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dobutamine.Approved
DofetilideAmoxapine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronAmoxapine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneAmoxapine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineAmoxapine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Amoxapine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Amoxapine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Amoxapine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Amoxapine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Doxofylline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Amoxapine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Illicit
DronedaroneDronedarone may increase the antihypertensive activities of Amoxapine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Drotebanol.Experimental, Illicit
DroxidopaAmoxapine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Amoxapine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dyclonine.Approved
EcabetThe serum concentration of Amoxapine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Amoxapine can be increased when it is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Amoxapine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Efonidipine.Approved, Investigational
ElafinThe serum concentration of Amoxapine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amoxapine.Approved, Investigational
EliglustatAmoxapine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Amoxapine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Amoxapine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Amoxapine can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Amoxapine is combined with Eperisone.Approved, Investigational
EphedraAmoxapine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineAmoxapine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineAmoxapine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineAmoxapine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.Approved
ErgotamineAmoxapine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinAmoxapine may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amoxapine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amoxapine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etafedrine.Approved
EthanolAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethotoin.Approved
Ethyl biscoumacetateAmoxapine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineAmoxapine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etizolam.Approved
EtomidateAmoxapine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Amoxapine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ezogabine.Approved, Investigational
FaldaprevirThe serum concentration of Amoxapine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Felbamate.Approved
FelodipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Amoxapine is combined with Fendiline.Withdrawn
FenoterolThe therapeutic efficacy of Fenoterol can be decreased when used in combination with Amoxapine.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fexofenadine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Amoxapine is combined with Fish oil.Approved, Nutraceutical
FlecainideAmoxapine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fludiazepam.Approved, Illicit
FluindioneAmoxapine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flunarizine.Approved
FlunisolideThe therapeutic efficacy of Flunisolide can be decreased when used in combination with Amoxapine.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amoxapine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Amoxapine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluspirilene.Approved, Investigational
Fluticasone furoateThe therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine.Approved
Fluticasone propionateThe therapeutic efficacy of Fluticasone propionate can be decreased when used in combination with Amoxapine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.Approved, Investigational
FormoterolThe therapeutic efficacy of Formoterol can be decreased when used in combination with Amoxapine.Approved, Investigational
FosamprenavirThe serum concentration of Amoxapine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Amoxapine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Amoxapine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Amoxapine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amoxapine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Gabapentin Enacarbil.Approved, Investigational
GabexateThe serum concentration of Amoxapine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidAmoxapine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Amoxapine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amoxapine.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Amoxapine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemifloxacinAmoxapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineAmoxapine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Amoxapine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Amoxapine can be increased when it is combined with GM6001.Experimental
GoserelinAmoxapine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAmoxapine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzAmoxapine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineAmoxapine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Amoxapine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Amoxapine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Amoxapine can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hexoprenaline.Approved, Withdrawn
HigenamineAmoxapine may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amoxapine.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Amoxapine.Experimental
HydrocodoneAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amoxapine.Approved, Illicit
HydroxyamphetamineAmoxapine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
IbutilideAmoxapine may increase the QTc-prolonging activities of Ibutilide.Approved
IdraparinuxThe serum concentration of Amoxapine can be increased when it is combined with Idraparinux.Investigational
IloperidoneAmoxapine may increase the antihypertensive activities of Iloperidone.Approved
ImidaprilThe serum concentration of Amoxapine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may increase the antihypertensive activities of Amoxapine.Approved
IndacaterolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Amoxapine.Approved
IndalpineIndalpine may increase the serotonergic activities of Amoxapine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Amoxapine.Withdrawn
IndinavirThe metabolism of Amoxapine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Amoxapine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Amoxapine.Approved, Investigational
Iofetamine I-123Amoxapine may increase the stimulatory activities of Iofetamine I-123.Approved
Ioflupane I-123Amoxapine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IpratropiumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Amoxapine.Approved
IproclozideIproclozide may increase the serotonergic activities of Amoxapine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Amoxapine.Withdrawn
IsocarboxazidThe therapeutic efficacy of Amoxapine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amoxapine.Approved, Vet Approved
IsoflurophateThe serum concentration of Amoxapine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneAmoxapine may increase the vasopressor activities of Isometheptene.Approved
IsoniazidThe metabolism of Amoxapine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Isoprenaline.Approved, Investigational
IsoxsuprineAmoxapine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Isradipine.Approved, Investigational
IxazomibThe serum concentration of Amoxapine can be increased when it is combined with Ixazomib.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Amoxapine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Amoxapine.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the antihypertensive activities of Amoxapine.Approved
LacidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Amoxapine.Investigational
LenvatinibAmoxapine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LepirudinThe serum concentration of Amoxapine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Amoxapine can be increased when it is combined with Letaxaban.Investigational
LeuprolideAmoxapine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levodopa.Approved
LevofloxacinAmoxapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Amoxapine.Approved, Investigational
LevonordefrinAmoxapine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amoxapine.Approved
LevosalbutamolThe therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Amoxapine.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Amoxapine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Amoxapine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Amoxapine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Amoxapine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Amoxapine.Approved
LisdexamfetamineAmoxapine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Amoxapine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amoxapine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Amoxapine can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Amoxapine is combined with Loperamide.Approved
LopinavirThe metabolism of Amoxapine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Amoxapine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amoxapine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Amoxapine can be increased when it is combined with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amoxapine.Approved
LumefantrineAmoxapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Amoxapine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Amoxapine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Amoxapine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Amoxapine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Medazepam.Experimental
MedetomidineAmoxapine may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Amoxapine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Amoxapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Amoxapine is combined with Menthol.Approved
MephedroneAmoxapine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineAmoxapine may increase the vasopressor activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.Approved, Investigational
MetaraminolAmoxapine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amoxapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineAmoxapine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.Approved, Vet Approved
MethohexitalThe metabolism of Amoxapine can be increased when combined with Methohexital.Approved
MethotrimeprazineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineAmoxapine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineAmoxapine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methsuximide.Approved
MethyldopaAmoxapine may decrease the antihypertensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methylecgonine.Experimental
Methylene blueAmoxapine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amoxapine.Approved, Investigational
MethylphenobarbitalThe metabolism of Amoxapine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amoxapine.Approved
MibefradilThe risk or severity of hypotension can be increased when Amoxapine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.Approved, Illicit
MidodrineAmoxapine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineAmoxapine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Amoxapine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Amoxapine.Approved, Investigational
MilnacipranMilnacipran may increase the serotonergic activities of Amoxapine.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Amoxapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Investigational
MirabegronThe metabolism of Amoxapine can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Amoxapine.Investigational
MirtazapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAAmoxapine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Amoxapine.Approved, Investigational
MoexiprilThe serum concentration of Amoxapine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Molindone.Approved
MometasoneThe therapeutic efficacy of Mometasone can be decreased when used in combination with Amoxapine.Approved, Vet Approved
MontelukastThe therapeutic efficacy of Montelukast can be decreased when used in combination with Amoxapine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Amoxapine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amoxapine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Mosapramine.Experimental
MoxifloxacinAmoxapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amoxapine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amoxapine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
NafamostatThe serum concentration of Amoxapine can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of hypotension can be increased when Amoxapine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amoxapine.Approved
NaphazolineAmoxapine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Naratriptan.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Amoxapine.Approved, Withdrawn
NelfinavirThe serum concentration of Amoxapine can be increased when it is combined with Nelfinavir.Approved
NevirapineThe metabolism of Amoxapine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Amoxapine.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Amoxapine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Amoxapine.Approved, Investigational
NicorandilAmoxapine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nifedipine.Approved
NiguldipineAmoxapine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibAmoxapine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Amoxapine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amoxapine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amoxapine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nordazepam.Approved
NorepinephrineAmoxapine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfenefrineAmoxapine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Amoxapine.Approved
NylidrinAmoxapine may decrease the vasoconstricting activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Amoxapine.Withdrawn
OctopamineAmoxapine may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinAmoxapine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the antihypertensive activities of Amoxapine.Approved, Investigational
OlodaterolThe therapeutic efficacy of Olodaterol can be decreased when used in combination with Amoxapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Olopatadine.Approved
OmalizumabThe therapeutic efficacy of Omalizumab can be decreased when used in combination with Amoxapine.Approved, Investigational
OmapatrilatThe serum concentration of Amoxapine can be increased when it is combined with Omapatrilat.Investigational
OndansetronAmoxapine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Amoxapine is combined with Opium.Approved, Illicit
OrciprenalineThe therapeutic efficacy of Orciprenaline can be decreased when used in combination with Amoxapine.Approved
OrphenadrineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Amoxapine is combined with Osanetant.Investigational
OtamixabanThe serum concentration of Amoxapine can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Amoxapine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amoxapine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amoxapine.Approved, Illicit, Investigational
OxyfedrineAmoxapine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineAmoxapine may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amoxapine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxypertine.Experimental
PaliperidonePaliperidone may increase the antihypertensive activities of Amoxapine.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Amoxapine.Approved, Investigational
PanobinostatThe serum concentration of Amoxapine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Amoxapine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amoxapine.Approved, Investigational
PazopanibAmoxapine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Penfluridol.Experimental
PentamidineAmoxapine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine.Approved, Vet Approved
PentobarbitalThe metabolism of Amoxapine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Amoxapine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Amoxapine.Approved, Investigational
PerflutrenAmoxapine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideAmoxapine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Amoxapine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Amoxapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amoxapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amoxapine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Amoxapine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenazocine.Experimental
PhendimetrazineAmoxapine may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Amoxapine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenibut.Experimental
PhenindioneAmoxapine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Amoxapine.Withdrawn
PhenobarbitalThe metabolism of Amoxapine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Amoxapine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amoxapine.Withdrawn
PhenprocoumonAmoxapine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineAmoxapine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineAmoxapine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineAmoxapine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amoxapine.Approved, Vet Approved
PhosphoramidonThe serum concentration of Amoxapine can be increased when it is combined with Phosphoramidon.Experimental
PimozideAmoxapine may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Amoxapine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe therapeutic efficacy of Pirbuterol can be decreased when used in combination with Amoxapine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Amoxapine.Approved
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Amoxapine.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Amoxapine.Withdrawn
PizotifenAmoxapine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Amoxapine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pomalidomide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
PramipexoleAmoxapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pramocaine.Approved
PranlukastThe therapeutic efficacy of Pranlukast can be decreased when used in combination with Amoxapine.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Amoxapine.Approved
PregabalinThe therapeutic efficacy of Amoxapine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolAmoxapine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Amoxapine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prilocaine.Approved
PrimaquineAmoxapine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Amoxapine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Amoxapine can be increased when it is combined with Prinomastat.Investigational
ProcainamideAmoxapine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the serotonergic activities of Amoxapine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Amoxapine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.Approved, Vet Approved
PromazinePromazine may increase the antihypertensive activities of Amoxapine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Amoxapine.Approved
PropanididThe risk or severity of adverse effects can be increased when Amoxapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Proparacaine.Approved, Vet Approved
PropericiazineAmoxapine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Amoxapine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Amoxapine.Vet Approved
PropiverineAmoxapine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Amoxapine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Amoxapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Amoxapine is combined with PSD502.Investigational
PseudoephedrineAmoxapine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amoxapine.Approved, Illicit
QuetiapineQuetiapine may increase the antihypertensive activities of Amoxapine.Approved
QuinaprilThe serum concentration of Amoxapine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineAmoxapine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineAmoxapine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Amoxapine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineAmoxapine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Raclopride.Investigational
RactopamineAmoxapine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Amoxapine can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Amoxapine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Amoxapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amoxapine.Approved
RemikirenThe serum concentration of Amoxapine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Remoxipride.Approved, Withdrawn
ReproterolAmoxapine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amoxapine.Approved, Investigational
RilmenidineAmoxapine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolAmoxapine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Amoxapine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ritanserin.Investigational
RitobegronAmoxapine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Amoxapine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Amoxapine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Rizatriptan.Approved
RoflumilastThe therapeutic efficacy of Roflumilast can be decreased when used in combination with Amoxapine.Approved
RolapitantThe metabolism of Amoxapine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineAmoxapine may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleAmoxapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ropivacaine.Approved
RotigotineAmoxapine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Amoxapine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amoxapine.Approved
S-3304The serum concentration of Amoxapine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Amoxapine.Withdrawn
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Amoxapine.Approved, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Amoxapine.Approved
SaquinavirThe serum concentration of Amoxapine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Amoxapine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Amoxapine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Amoxapine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Amoxapine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amoxapine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amoxapine.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Amoxapine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Amoxapine.Approved
SimeprevirThe serum concentration of Amoxapine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Amoxapine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Amoxapine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sodium phosphate.Approved
SolabegronAmoxapine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolAmoxapine may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Amoxapine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Amoxapine can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Amoxapine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.Approved, Investigational
SulfisoxazoleAmoxapine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sumatriptan.Approved, Investigational
SuvorexantAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineAmoxapine may decrease the vasoconstricting activities of Synephrine.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amoxapine.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Amoxapine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Amoxapine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Amoxapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Amoxapine.Approved
TelaprevirThe serum concentration of Amoxapine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinAmoxapine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinAmoxapine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amoxapine.Approved, Investigational
TemocaprilThe serum concentration of Amoxapine can be increased when it is combined with Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Amoxapine.Approved
TerbinafineThe metabolism of Amoxapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Amoxapine.Approved
TerodilineThe risk or severity of hypotension can be increased when Amoxapine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Amoxapine.Experimental
TetrabenazineAmoxapine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tetrodotoxin.Investigational
TetryzolineAmoxapine may increase the vasopressor activities of Tetryzoline.Approved
ThalidomideAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Amoxapine.Approved
ThiamylalThe metabolism of Amoxapine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Amoxapine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Amoxapine.Withdrawn
ThiopentalThe metabolism of Amoxapine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Thiopropazate.Experimental
ThioproperazineAmoxapine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Amoxapine.Approved, Withdrawn
ThiorphanThe serum concentration of Amoxapine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amoxapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Amoxapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
TioclomarolAmoxapine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Amoxapine.Approved
TipranavirThe metabolism of Amoxapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineAmoxapine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Amoxapine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amoxapine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Amoxapine is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the serotonergic activities of Amoxapine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Amoxapine.Approved
ToremifeneAmoxapine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolAmoxapine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Amoxapine can be increased when it is combined with Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Amoxapine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the serotonergic activities of Amoxapine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Amoxapine.Approved, Investigational
TretoquinolAmoxapine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamcinoloneThe therapeutic efficacy of Triamcinolone can be decreased when used in combination with Amoxapine.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amoxapine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Amoxapine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Amoxapine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Amoxapine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Amoxapine is combined with Trimethadione.Approved
TrimipramineAmoxapine may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Amoxapine.Approved
TropisetronTropisetron may increase the serotonergic activities of Amoxapine.Approved, Investigational
TulobuterolThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Amoxapine.Investigational
UbenimexThe serum concentration of Amoxapine can be increased when it is combined with Ubenimex.Experimental, Investigational
UdenafilUdenafil may increase the hypotensive activities of Amoxapine.Approved, Investigational
UlinastatinThe serum concentration of Amoxapine can be increased when it is combined with Ulinastatin.Investigational
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Amoxapine.Approved
UrapidilUrapidil may increase the antihypertensive activities of Amoxapine.Investigational
Valproic AcidThe serum concentration of Amoxapine can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibAmoxapine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Amoxapine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amoxapine.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Amoxapine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Veralipride.Experimental
VerapamilAmoxapine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vigabatrin.Approved
VilanterolThe therapeutic efficacy of Vilanterol can be decreased when used in combination with Amoxapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Amoxapine.Approved
VildagliptinThe serum concentration of Amoxapine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Amoxapine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Amoxapine.Approved, Investigational
WarfarinAmoxapine may increase the anticoagulant activities of Warfarin.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Amoxapine is combined with WIN 55212-2.Experimental
XamoterolAmoxapine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Amoxapine is combined with Xenon.Experimental
XimelagatranThe serum concentration of Amoxapine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineAmoxapine may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineAmoxapine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amoxapine.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Amoxapine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe therapeutic efficacy of Zafirlukast can be decreased when used in combination with Amoxapine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ziconotide.Approved
ZileutonThe therapeutic efficacy of Zileuton can be decreased when used in combination with Amoxapine.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the serotonergic activities of Amoxapine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Amoxapine.Approved
ZofenoprilThe serum concentration of Amoxapine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amoxapine.Approved, Investigational
ZolpidemAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amoxapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Amoxapine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company

US3663696
General References
Not Available
External Links
Human Metabolome Database
HMDB0014683
KEGG Drug
D00228
PubChem Compound
2170
PubChem Substance
46509117
ChemSpider
2085
BindingDB
22870
ChEBI
2675
ChEMBL
CHEMBL1113
Therapeutic Targets Database
DAP001149
PharmGKB
PA448405
IUPHAR
201
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Amoxapine
ATC Codes
N06AA17 — Amoxapine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Sandoz inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
Packagers
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Pharmaceutical Utilization Management Program VA Inc.
  • Stat Rx Usa
  • United Research Laboratories Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral100 mg
TabletOral25 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Amoxapine 30 150 mg tablet Bottle82.15USD bottle
Amoxapine 150 mg tablet2.63USD tablet
Amoxapine 100 mg tablet1.7USD tablet
Amoxapine 50 mg tablet1.02USD tablet
Amoxapine 25 mg tablet0.63USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)175-176Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; US. Patent 3,663,696; May 16, 1972; assigned to American Cyanamid Company Howell, C.F., Hardy, R.A., Jr. and Quinones, N.Q.; U.S. Patent 3,681,357; August 1, 1972; assigned to American Cyanamid Company
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP2.82ALOGPS
logP3.08ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area36.86 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity89.82 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.988
Caco-2 permeable-0.5488
P-glycoprotein substrateSubstrate0.8068
P-glycoprotein inhibitor IInhibitor0.7622
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6414
CYP450 2C9 substrateNon-substrate0.7682
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5168
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5472
Ames testNon AMES toxic0.7277
CarcinogenicityNon-carcinogens0.8159
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6376
hERG inhibition (predictor II)Inhibitor0.7874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-052b-4490000000-6bbd0d2c0c8fe332c636
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-044i-0169000000-d1665f2e6d27a9efaa39
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002f-0940000000-9bf5c13f1f2b9b04f465
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dl-2690000000-0e598ca107ca857b8f06

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxazepines. These are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxazepines
Sub Class
Dibenzoxazepines
Direct Parent
Dibenzoxazepines
Alternative Parents
Diarylethers / Piperazines / Imidolactams / Benzenoids / Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Dialkylamines / Carboxamidines / Azacyclic compounds
show 3 more
Substituents
Dibenzoxazepine / Diaryl ether / Aryl chloride / Aryl halide / 1,4-diazinane / Piperazine / Imidolactam / Benzenoid / Amidine / Carboxylic acid amidine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dibenzooxazepine (CHEBI:2675)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology. 1994 Mar-Apr;33(3-4):433-40. [PubMed:7984281]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571]
  2. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Richelson E: Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc. 1983 Jan;58(1):40-6. [PubMed:6130192]
  2. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Details
14. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Glusa E, Pertz HH: Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000 Jun;130(3):692-8. [PubMed:10821800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Gozlan H, Saddiki-Traki F, Merahi N, Laguzzi R, Hamon M: [Preclinical pharmacology of amoxapine and amitriptyline. Implications of serotoninergic and opiodergic systems in their central effect in rats]. Encephale. 1991 Dec;17 Spec No 3:415-22. [PubMed:1666997]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Details
23. Histamine H4 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Histamine receptor activity
Specific Function
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agoni...
Gene Name
HRH4
Uniprot ID
Q9H3N8
Uniprot Name
Histamine H4 receptor
Molecular Weight
44495.375 Da
References
  1. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. Epub 2005 Jun 9. [PubMed:15947036]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5. [PubMed:1966571]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8]
  2. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Shin HC, Kim HR, Cho HJ, Yi H, Cho SM, Lee DG, Abd El-Aty AM, Kim JS, Sun D, Amidon GL: Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos. 2009 Nov;30(8):411-21. doi: 10.1002/bdd.675. [PubMed:19746353]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Drug created on June 13, 2005 07:24 / Updated on June 13, 2018 22:18